ProCE Banner Activity

MITO23: Phase III Trial of Trabectedin vs Investigator’s Choice of Chemotherapy for Recurrent Ovarian Cancer With BRCA Mutation or BRCAness Phenotype

Slideset Download
Conference Coverage
In MITO23, trabectedin failed to improve survival compared with investigator’s choice of single-agent chemotherapy in patients with BRCA-mutant or BRCAness phenotype recurrent ovarian cancer.

Released: June 17, 2022

Expiration: June 16, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab